Cabio Biotech (Wuhan) Co (SHSE:688089) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688089 Cabio Biotech (Wuhan) Co Ltd SHSE:688089
67 GF Score
Price ¥10.44
GF Value ¥20.70
Valuation Possible Value Trap
! 10 Warning Signs
View Full Analysis

What is Cabio Biotech (Wuhan) Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cabio Biotech (Wuhan) Co Valuation Rank Related Terms

SHSE:688089
67GF Score
Cabio Biotech (Wuhan) Co Ltd SHSE:688089
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cabio Biotech (Wuhan) Co (SHSE:688089) Overvalued in 2026?

Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co stock appears to be undervalued. The current stock price of ¥10.44 is trading 49.6% below its estimated GF Value™ of ¥20.70. GuruFocus considers Cabio Biotech (Wuhan) Co to be Possible Value Trap.

Key valuation signals for SHSE:688089:

  • Valuation Rank:
  • GF Value™: ¥20.70 vs. price of ¥10.44 (49.6% below fair value)
  • GF Score™: 67/100 with 10 warning signs

No single metric tells the full story. See the SHSE:688089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cabio Biotech (Wuhan) Co Business Description

Address No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
67GF Score

Get the complete analysis for SHSE:688089

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.44
Price
¥20.70
GF Value